First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer

Overview of attention for news story in Nature Reviews Drug Discovery

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 46 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 53 X posts from 46 X users, with an upper bound of 139,267 followers.

Anktiva plus BCG Vaccine: "The first-in-class IL-15 receptor agonist is designed to activate and drive the proliferation of natural killer (NK) cells, CD8+ killer T cells and memory killer T cells." https://t.co/LgN0M6zvUr

25 May 2024

Reply Repost Favourite

RT @renesugar: @RenzPolster Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect https://t.co/wa0Uu…

23 May 2024

Reply Repost Favourite

@RenzPolster Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect https://t.co/wa0Uu8484c https://t.co/DmcZlc1zWb "BCG is the most common intravesical immunotherapy for treating early-stage bladder cancer." https:

23 May 2024

Reply Repost Favourite

https://t.co/5q5puv6g2W "The first-in-class IL-15 receptor agonist is designed to activate and drive the proliferation of natural killer (NK) cells, CD8+ killer T cells and memory killer T cells."

22 May 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 49 additional X posts.